

The following is a list of currently available studies (clinical trials) offered to potentially eligible patients seen in the Richard A. Henson Cancer Institute. This list is updated periodically. For additional information on any studies listed on this page, please contact the Richard A. Henson Research Institute - Research Department @ (410) 543-7017. For study-specific information, go to ClinicalTrials.gov and type the study-specific NCT number in the “Other terms” box.

BREAST

- | | |
|------------------|--|
| Alliance A011502 | A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: (ABC) NCT02927249 |
| NRG-BR003 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer NCT02488967 |
| A011401 | Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer NCT02750826 |
| A221505 | Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction NCT03414970 |
| S1418/NRG-BR006 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy NCT02954874 |

LUNG

- | | |
|------------------|---|
| Alliance A151216 | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial. For Patients With Resectable or Resected Lung Cancer NCT02194738 |
|------------------|---|

Updated November 2018

- A081105 Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer **NCT02193282**
- E4512 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein **NCT02201992**
- EA5142 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers **NCT02595944**
- CALGB 30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide **NCT00632853**
- NRG-LU002 Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial **NCT03137771**
- SWOG 1400** Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer **NCT02154490**
- S1400F A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY) **NCT 2016-01597**
- EA5161 Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC) **NCT03382561**

Gastrointestinal

- A021502 Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy For Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) **NCT02912559**

Genitourinary

- NRG-GU002 Phase II/III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following RP with or without Adjuvant Docetaxel **NCT03070886**

Updated November 2018

RTOG 0924 Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial **NCT01368588**

NRG-GU005 Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer **NCT03367702**

Gynecologic

TESARO PR-3000-02-004 A Phase II, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Niraparib Combined With Bevacizumab as Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab **NCT03326193**

Multiple Myeloma

E1A11 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) **NCT01863550**